Clinical Outcomes of Epidermal Growth Factor Receptor (EGFR) Mutated Metastatic Non-Small Cell Lung Cancer in Kurdistan Region: A Retrospective Study

Lung cancer remains one of the most formidable challenges in modern medicine, responsible for more deaths worldwide than any other malignancy. Within this broad category, a specific type known as non-small cell lung cancer accounts for the vast majority of cases. For decades, treatment options were limited, often relying on chemotherapy that attacked all rapidly dividing cells, healthy or not. However, a significant shift occurred when scientists discovered that many of these cancers are driven by specific errors in a protein called the epidermal growth factor receptor, or EGFR. Think of this protein as a switch on the surface of a cell that tells it when to grow. In some patients, this switch gets stuck in the "on" position due to a genetic mutation, causing the cell to multiply uncontrollably. This discovery opened the door to targeted therapies: drugs designed specifically to turn that stuck switch off. These medications, known as tyrosine kinase inhibitors, have transformed the outlook for many patients, but their real-world effectiveness can vary depending on where a patient lives, their specific genetic makeup, and their overall health.

In the Kurdistan Region of Iraq, where lung cancer is a growing public health concern, doctors have been using these targeted drugs, yet comprehensive data on how well they work for local patients has been scarce. To fill this gap, a team of researchers from the Kurdistan Higher Council of Medical Specialties conducted a detailed review of medical records from four major hospitals in the region. They looked back at the histories of 119 patients who had been diagnosed with metastatic non-small cell lung cancer carrying the specific EGFR mutation. The study focused on two critical measures of success: how long patients lived without their disease getting worse, and how long they lived in total. By examining records collected between 2013 and 2025, the team aimed to understand which factors helped patients survive longer and whether the newer, third-generation drug, Osimertinib, offered a clear advantage over the older, first-generation treatments.

The researchers found that the genetic landscape of these patients closely mirrored global trends, with the most common mutation occurring in a specific section of the gene known as Exon 19, found in nearly 70 percent of the group. The second most frequent mutation was located in Exon 21. When it came to treatment, the majority of patients, about 71 percent, received the older first-generation drugs, while roughly 19 percent were treated with Osimertinib. The results showed a distinct difference in how long patients could go before their cancer progressed. Those treated with Osimertinib remained free from disease progression for a median of 24.1 months, compared to just 11 months for those on the first-generation drugs. This difference was statistically significant, suggesting that the newer drug provided a more durable period of control over the cancer.

However, the story of survival was more complex when looking at the total length of life. Despite the longer time without progression, the study did not find a statistically significant difference in the overall survival time between the two groups. Patients on Osimertinib lived a median of 23.9 months, while those on the older drugs lived a median of 22.7 months. The researchers noted that this lack of difference might be influenced by how the data was collected; overall survival was measured from the date of diagnosis rather than the start of treatment. Since some patients received chemotherapy while waiting for genetic test results before starting the targeted therapy, the time between diagnosis and treatment could have blurred the comparison. Furthermore, the study suggested that factors other than the specific drug chosen played a major role in how long a patient lived.

The analysis revealed that a patient's general health and age were powerful predictors of their outcome. Patients who maintained a good level of physical function, able to carry out daily activities without significant restriction, lived significantly longer than those who were more limited by their illness. Similarly, younger patients tended to survive longer than older ones. The type of genetic mutation also mattered; patients with rare or "uncommon" mutations had worse survival outcomes compared to those with the common Exon 19 deletion. Interestingly, while smoking status appeared to influence survival in initial comparisons, it did not remain a significant factor once other variables like age and health status were taken into account.

This study provides a crucial snapshot of lung cancer care in a region where such data was previously unavailable. It confirms that the newer generation of targeted drugs can delay disease progression more effectively than older versions, offering patients a longer period of stability. Yet, it also highlights that the ultimate length of a patient's life is shaped by a combination of factors, including their physical resilience, their age, and the specific nature of their genetic mutation. While the newer drug offers a clear benefit in controlling the disease for a longer time, the researchers emphasize that optimizing care requires looking beyond the medication alone to consider the whole patient. As the medical community in the region continues to gather evidence, these findings serve as a foundation for refining treatment strategies and improving outcomes for those facing this difficult diagnosis.